Compass Therapeutics' Pipeline Progress and 2025 Losses Reveal Oncology Strategy Risks and Catalysts

Compass Therapeutics reported a Q4 net loss of $15.72 million and a full-year net loss of $66.49 million. The company advanced multiple oncology programs, including the Phase 2/3 COMPANION-002 study of tovecimig and secured FDA clearance for CTX-10726. Investors are focused on the upcoming survival data from COMPANION-002 and the broadening pipeline, which is expected to fund operations into 2028. The company's investment narrative hinges on its bispecific oncology platform converting clinical momentum into eventual commercial products before the cash runway runs out.